Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
No standard chemotherapy is available after disease progression or anaphylaxis during platinum chemotherapy among patients with recurrent cervical cancer. Here we report the efficacy and toxicities of metronomic chemotherapy consisting of 50 mg of oral cyclophosphamide (CPA) daily and intravenous 15...
Saved in:
Main Authors: | Roze Isono-Taniguchi (Author), Mayako Goto (Author), Yumi Takimoto (Author), Tomoko Ueda (Author), Yu Wakimoto (Author), Kayo Inoue (Author), Kensuke Hori (Author), Kimihiko Ito (Author), Hiroshi Tsubamoto (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
by: Rose Isono-Nakata, et al.
Published: (2018) -
Weight-loss interventions and levonorgestrel intrauterine system implantation for early-stage endometrial cancer and atypical endometrial hyperplasia to reduce perioperative risk of severely obese patients
by: Roze Isono-Taniguchi, et al.
Published: (2023) -
Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer
by: Ioannis Alagkiozidis, et al.
Published: (2015) -
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
by: Kayo Inoue, et al.
Published: (2020) -
Clinical Applications of Metronomic Chemotherapy
Published: (2023)